Bridget E. Bunner

Array ( [id] => 11204076 [patent_doc_number] => 09433687 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-06 [patent_title] => 'Anti-Notch3 antibodies and antibody-drug conjugates' [patent_app_type] => utility [patent_app_number] => 14/073273 [patent_app_country] => US [patent_app_date] => 2013-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 32 [patent_no_of_words] => 33667 [patent_no_of_claims] => 64 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14073273 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10988926 [patent_doc_number] => 20160185871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-30 [patent_title] => 'PREVENTIVE OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASE' [patent_app_type] => utility [patent_app_number] => 14/785844 [patent_app_country] => US [patent_app_date] => 2013-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17752 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14785844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10911765 [patent_doc_number] => 20140314782 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-23 [patent_title] => 'ANTI-NOTCH2 NRR ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/051699 [patent_app_country] => US [patent_app_date] => 2013-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 51110 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14051699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11324988 [patent_doc_number] => 20160355601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => 'Methods and Compositions for the Treatment of Pancreatic Cancer' [patent_app_type] => utility [patent_app_number] => 14/429278 [patent_app_country] => US [patent_app_date] => 2013-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 19048 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14429278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347566 [patent_doc_number] => 20150232570 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'Methods of Treating Hematological Malignancies with Notch1 Antibodies' [patent_app_type] => utility [patent_app_number] => 14/429497 [patent_app_country] => US [patent_app_date] => 2013-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 31436 [patent_no_of_claims] => 77 [patent_no_of_ind_claims] => 46 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14429497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9338366 [patent_doc_number] => 20140065149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-06 [patent_title] => 'Methods for Treating Melanoma' [patent_app_type] => utility [patent_app_number] => 14/020567 [patent_app_country] => US [patent_app_date] => 2013-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 29960 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14020567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9307101 [patent_doc_number] => 20140045775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-13 [patent_title] => 'SHORT-FORM HUMAN MD-2 AS A NEGATIVE REGULATOR OF TOLL-LIKE RECEPTOR 4 SIGNALING' [patent_app_type] => utility [patent_app_number] => 14/010362 [patent_app_country] => US [patent_app_date] => 2013-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 18228 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14010362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9901017 [patent_doc_number] => 20150056217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-26 [patent_title] => 'USE OF TOLL-LIKE RECEPTOR-9 AGONISTS, TOLL-LIKE RECEPTOR-4 ANTAGONISTS, AND/OR NUCLEAR OLIGOMERIZATION DOMAIN-2 AGONISTS FOR THE TREATMENT OR PREVENTION OF TOLL-LIKE RECEPTOR-4 ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/010232 [patent_app_country] => US [patent_app_date] => 2013-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 11937 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14010232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9901017 [patent_doc_number] => 20150056217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-26 [patent_title] => 'USE OF TOLL-LIKE RECEPTOR-9 AGONISTS, TOLL-LIKE RECEPTOR-4 ANTAGONISTS, AND/OR NUCLEAR OLIGOMERIZATION DOMAIN-2 AGONISTS FOR THE TREATMENT OR PREVENTION OF TOLL-LIKE RECEPTOR-4 ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/010232 [patent_app_country] => US [patent_app_date] => 2013-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 11937 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14010232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9396102 [patent_doc_number] => 20140093508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-03 [patent_title] => 'Toll-Like 3 Receptor Antagonists' [patent_app_type] => utility [patent_app_number] => 13/973187 [patent_app_country] => US [patent_app_date] => 2013-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 34863 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13973187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318562 [patent_doc_number] => 20150203565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'B-CELL ACTIVATING FACTOR FOR INCREASING MUCOSAL IMMUNITY OF INFANTS AS WELL AS SUCKLINGS AND A PREPARATION CONTAINING THIS FACTOR' [patent_app_type] => utility [patent_app_number] => 14/420821 [patent_app_country] => US [patent_app_date] => 2013-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3083 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14420821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9262096 [patent_doc_number] => 20130344025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-26 [patent_title] => 'METHOD FOR THE ADMINISTRATION OF LIGANDS, AGONISTS OF LIGANDS OF THE TNF FAMILY WITH REDUCED TOXICITY' [patent_app_type] => utility [patent_app_number] => 13/966559 [patent_app_country] => US [patent_app_date] => 2013-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5570 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13966559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347563 [patent_doc_number] => 20150232568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'ANTI-JAGGED ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/421103 [patent_app_country] => US [patent_app_date] => 2013-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 27144 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14421103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9181253 [patent_doc_number] => 20130323239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-05 [patent_title] => 'MODULATION OF PILR RECEPTORS TO TREAT SEPSIS' [patent_app_type] => utility [patent_app_number] => 13/962835 [patent_app_country] => US [patent_app_date] => 2013-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18536 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13962835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10506161 [patent_doc_number] => 09234028 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-12 [patent_title] => 'Targeted therapeutics based on engineered proteins that bind EGFR' [patent_app_type] => utility [patent_app_number] => 13/956952 [patent_app_country] => US [patent_app_date] => 2013-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 31459 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13956952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9191015 [patent_doc_number] => 20130330330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-12 [patent_title] => 'ANTI-IL-TIF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/953975 [patent_app_country] => US [patent_app_date] => 2013-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 65156 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13953975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9147833 [patent_doc_number] => 20130302356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-14 [patent_title] => 'Method of Treating Cancer with DLL4 Antagonist and Chemotherapeutic Agent' [patent_app_type] => utility [patent_app_number] => 13/948919 [patent_app_country] => US [patent_app_date] => 2013-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15005 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13948919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11921575 [patent_doc_number] => 09789135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-17 [patent_title] => 'Enhanced reconstitution and autoreconstitution of the hematopoietic compartment' [patent_app_type] => utility [patent_app_number] => 14/415325 [patent_app_country] => US [patent_app_date] => 2013-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 48425 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14415325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9869039 [patent_doc_number] => 08956811 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-17 [patent_title] => 'Diagnosis of malignant neoplasms using anti-Notch3 antibodies' [patent_app_type] => utility [patent_app_number] => 13/942421 [patent_app_country] => US [patent_app_date] => 2013-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 16347 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13942421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10265946 [patent_doc_number] => 20150150943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'USE OF SDF-1 TO IMPROVE ISCHEMIC MYOCARDIAL FUNCTION' [patent_app_type] => utility [patent_app_number] => 13/938608 [patent_app_country] => US [patent_app_date] => 2013-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 50 [patent_no_of_words] => 17440 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13938608 [rel_patent_id] =>[rel_patent_doc_number] =>)